
    
      The purpose of the Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases
      in Pregnancy Project is to follow pregnant women or women who have delivered a baby, who have
      been treated with Stelara or Tremfya within 3 months of their last menstrual period (LMP) or
      during pregnancy to evaluate the possible effect of this medication on the pregnancy outcome
      including child development and growth up to one year of age.
    
  